Pharma — Oktober 2023
-
Amerikansk biotekaktie får jackpot: Lilly lægger 10 mia. kr. på bordet Amerikansk biotekaktie får jackpot: Lilly lægger 10 mia. kr. på bordet
-
ALK får løftet anbefaling og kursmål af norsk storbank https://www.proinvestor.com/investornyt/1058352/alk-far-loftet-anbefaling-og-kursmal-af-norsk-storbank
-
Alk-Abelló spurter frem i rødt aktiemarked efter varm anbefaling https://www.proinvestor.com/investornyt/1058385/alk-abello-spurter-frem-i-rodt-aktiemarked-efter-varm-anbefaling
-
Økonomer: Uden medicinsektoren er industriproduktionen i nedgang https://www.proinvestor.com/investornyt/1059995/okonomer-uden-medicinsektoren-er-industriproduktionen-i-nedgang
-
Dagens aktie er AbbVie Inc.
AbbVie er en amerikansk børsnoteret biofarmaceutisk virksomhed der opstod som spin-off af Abbott Laboratories
62+ mio. mennesker behandles årlig med produkter fra AbbVie på tværs af 60+ sygdomme.
Primære områder er Immunologi - Onkologi - Virologi - Neurologi - Æstetik
https://www.proinvestor.com/boards/116020 -
Lundbeck får løftet kursmålet hos Deutsche Bank https://www.proinvestor.com/investornyt/1061034/lundbeck-far-loftet-kursmalet-hos-deutsche-bank
-
ALK-Abelló med positive resultater fra studier med behandling af træpollenallergi hos børn https://www.proinvestor.com/investornyt/1062086/alk-abello-med-positive-resultater-fra-studier-med-behandling-af-traepollenallergi-hos-born
-
AbbVie : Phase 3 Study Of Skyrizi In Crohn's Disease Meets All Primary And Secondary Endpoints https://www.proinvestor.com/investornyt/1063771/abbvie-phase-3-study-of-skyrizi-in-crohns-disease-meets-all-primary-and-secondary-endpoints
-
Is Pfizer a Bad News Buy Right Now? https://www.proinvestor.com/investornyt/1066754/is-pfizer-a-bad-news-buy-right-now
-
AstraZeneca: 59% Of Patients Treated With Tagrisso + Chemotherapy Had Complete Brain Tumor Responses https://www.proinvestor.com/investornyt/1066859/astrazeneca-59-of-patients-treated-with-tagrisso-chemotherapy-had-complete-brain-tumor-responses
-
AZN : Imfinzi Combination Reduces Risk Of Disease Progression Or Death By 45% In Endometrial Cancer https://www.proinvestor.com/investornyt/1066848/azn-imfinzi-combination-reduces-risk-of-disease-progression-or-death-by-45-in-endometrial-cancer
-
AstraZeneca : Enhertu Approved In EU For Advanced Non-small Cell Lung Cancer Treatment https://www.proinvestor.com/investornyt/1067048/astrazeneca-enhertu-approved-in-eu-for-advanced-non-small-cell-lung-cancer-treatment
-
Lundbeck får højere kursmål hos SEB https://www.proinvestor.com/investornyt/1067580/lundbeck-far-hojere-kursmal-hos-seb
-
AbbVie Raises 2023 Adj. EPS Guidance; Announces 2024 Dividend Increase https://www.proinvestor.com/investornyt/1070014/abbvie-raises-2023-adj-eps-guidance-announces-2024-dividend-increase
-
Lundbecks kursmål løftet til 40 kr. af Citigroup https://www.proinvestor.com/investornyt/1071535/lundbecks-kursmal-loftet-til-40-kr-af-citigroup
dejligt med gode nyheder det må så gerne snart kunne ses på aktiekursen for 6 mdr. siden var vi i kurs 112 lad os komme derop igenHello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind